Chemomab Revenue and Competitors
Estimated Revenue & Valuation
- Chemomab's estimated annual revenue is currently $6.6M per year.
- Chemomab's estimated revenue per employee is $201,000
Employee Data
- Chemomab has 33 Employees.
Chemomab's People
Name | Title | Email/Phone |
---|---|---|
1 | Consulting VP, Investor & Public Relations, Strategic Communications | Reveal Email/Phone |
2 | VP, Global Clinical Development Operations | Reveal Email/Phone |
3 | Associate Director, Preclinical Development | Reveal Email/Phone |
4 | Clinical Trial Manager | Reveal Email/Phone |
5 | Project Manager | Reveal Email/Phone |
6 | Senior Clinical Research Associate | Reveal Email/Phone |
7 | Project Leader | Reveal Email/Phone |
8 | Research Assistant | Reveal Email/Phone |
Chemomab Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is Chemomab?
Chemomab Ltd. is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases. Chemomab is making great strides with its novel CM-101 proprietary platform, which hinders the fundamental function of the soluble chemokine CCL24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders. CM-101, the company's lead clinical candidate, is a first-in-class monoclonal antibody that targets CCL24. Chemomab has shown that CM-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action. Chemomab is actively advancing CM-101 into phase 2 studies to treat patients with liver fibrosis (Primary Sclerosing Cholangitis and Non-alcoholic Steatohepatitis) and patients suffering from skin and lung fibrosis (Systemic Sclerosis).
keywords:N/AN/A
Total Funding
33
Number of Employees
$6.6M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Chemomab News
Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases.
CHEMOMAB THERAPEUTICS LTD. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) ... and the related...
Chemomab is a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $6M | 33 | -43% | N/A |
#2 | $7.5M | 33 | 3% | N/A |
#3 | $4.8M | 33 | 32% | N/A |
#4 | $4.2M | 33 | 6% | N/A |
#5 | $6.7M | 33 | 0% | N/A |